Friendship Hospital Trials

Friendship Hospital	Welcome, Profile Billing Logout

71 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhang, Zhongtao

RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer

Terminated

RoW

Oxaliplatin plus S-1, SOX, S-1 only, S-1

Peking University Cancer Hospital & Institute

Gastric Cancer

09/21

KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Active, not recruiting

120

RoW

Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®

Merck Sharp & Dohme LLC

Gastric Cancer, Gastroesophageal Junction Cancer

02/24

04/25

NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting

480

RoW

Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Hepatocellular Carcinoma

08/24

12/26

NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting

878

RoW

JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Shanghai Junshi Bioscience Co., Ltd.

Gastric or Esophagogastric Junction Adenocarcinoma

06/26

07/28

TQB3454-III-01, NCT05987358: A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Not yet recruiting

165

RoW

TQB3454 tablets, TQB3454 tablets matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Biliary Carcinoma

12/26

NCT06312982: A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study

Recruiting

2/3

375

RoW

Tislelizumab

Beijing Friendship Hospital, Beijing Chao Yang Hospital, Peking University Cancer Hospital & Institute, CHINA-JAPEN FRIENDSHIP HOSPITAL, Peking Union Medical College Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University, Changhai Hospital, RenJi Hospital, Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Shandong Provincial Hospital, Zhongnan Hospital of Wuhan University & Second Clinical Hospital of Wuhan University, The First Affiliated Hospital of Zhengzhou University, West China School of Medicine and West China Hospital, Sichuan University, Sichuan Academy of Medical Sciences, The Sixth Affiliated Hospital, Sun Yat-sen University, The First Hospital of Jilin University, First Hospital of China Medical University, Army Medical Center of PLA, The First Affiliated Hospital of Anhui Medical University

Locally Advanced Rectal Carcinoma

12/26

NCT04258657: Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer

Not yet recruiting

RoW

paclitaxel-albumin and S-1

Beijing Friendship Hospital

Gastric Cancer

12/22

NCT04258644: Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Not yet recruiting

RoW

Camrelizumab+Apatinib+Paclitaxel-albumin+S-1

Beijing Friendship Hospital

Gastric Cancer

02/23

EXPLORE, NCT03038256: Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial

Recruiting

244

RoW

concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX

Peking University People's Hospital, Peking University Cancer Hospital & Institute, Beijing Friendship Hospital, Peking Union Medical College Hospital, Chinese PLA General Hospital, Shanghai Zhongshan Hospital, Fujian Medical University Union Hospital, Nanfang Hospital of Southern Medical University, Xijing Hospital, Hebei Medical University Fourth Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Affiliated Hospital of Hebei University

Rectal Cancer, Pathological Complete Response, Disease Free Survival

04/23

06/25

POLAR-STAR, NCT05245474: Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

Recruiting

186

RoW

Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)

Beijing Friendship Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Peking University People's Hospital, Peking University Cancer Hospital & Institute, BeiGene

Locally Advanced Rectal Cancer

03/24

09/29

NCT06475846: A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

Not yet recruiting

232

RoW

HRS5580, Ondansetron, blank preparation

Fujian Shengdi Pharmaceutical Co., Ltd.

Preventing of Postoperative Nausea and Vomiting in Adults

10/24

11/24

NCT06056804: Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Active, not recruiting

RoW

capecitabine, tislelizumab, thymalfasin, long-term radiotherapy

Beijing Friendship Hospital, Peking Union Medical College Hospital

Locally Advanced Rectal Cancer

12/24

07/27

THYMI, NCT06829355: "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

Recruiting

RoW

Thymalfasin (Thymosin alpha 1, Ta1), Regorafenib (BAY 73-4506), Tislelizumab (BGB-A317)

Beijing Friendship Hospital, Peking Union Medical College Hospital, Peking University People's Hospital

MCRC

12/25

12/27

NCT04461847: ESM Versus OM ï¼šA Randomized Controlled Trial

Recruiting

N/A

287

RoW

subcutaneous mastectomy, endoscopic subcutaneous mastectomy

Beijing Friendship Hospital

Endoscopic Subcutaneous Mastectomy

12/22

POSTER, NCT04012645: Perfusion Outcomes With Near Infrared-Indocyanine Green Imaging System in Laparoscopic Total Mesorectal Excision for Mid- or Low-rectal CanceR

Recruiting

N/A

547

RoW

application of near infrared-indocyanine green imaging system, Non-application of near infrared-indocyanine green imaging system

Zhongtao Zhang, Peking Union Medical College Hospital, Beijing Chao Yang Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chinese PLA General Hospital, Peking University People's Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Changhai Hospital, Ruijin Hospital, RenJi Hospital, Fudan University, Guangdong Provincial People's Hospital, Southern Medical University, China, First Hospital of China Medical University, The First Hospital of Jilin University, The First Affiliated Hospital with Nanjing Medical University, Fujian Medical University Union Hospital, First Affiliated Hospital of Chongqing Medical University, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Rectal Neoplasms

12/23

NACSOC, NCT02972541: Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer

Recruiting

N/A

248

RoW

Stenting with neoadjuvant chemotherapy, Stenting with immediate Surgery

Beijing Chao Yang Hospital

Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction

12/23

NCT06204497: The Safety and Efficiency of Stent-based Diverting Technique Versus Ileostomy in Rectal Cancer Patients

Recruiting

N/A

570

RoW

Stent-based Diverting Technique

Sir Run Run Shaw Hospital

Rectal Neoplasms

12/24

06/25

NCT04366999: Effectiveness of Bariatric Surgery for NAFLD/NASH

Recruiting

N/A

320

RoW

SG, RYGB, OAGB

Beijing Friendship Hospital, Beijing Tiantan Hospital, Beijing Hospital (only for Base-NAFLD), Beijing Shijitan Hospital, Capital Medical University Beijing Hospital (only for Base-NAFLD), Shanghai Jiao Tong University affiliated Sixth People's Hospital Beijing Hospital (only for Base-NAFLD), Huashan Hospital, Fudan University Beijing Hospital (only for Base-NAFLD), Beijing Chao Yang Hospital, Beijing Luhe Hospital, Capital Medical University, The First Hospital of Kunming, Bishan Hospital of Chongqiang Medical University, The First Hospital of Hebei Medical University

Bariatric Surgery Candidate, NAFLD, NASH With Fibrosis

12/24

12/26

ORDER, NCT05015283: Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission

Recruiting

N/A

248

RoW

The laparoscopic One-anastomosis gastric bypass will consist of:, The laparoscopic Roux-en-Y gastric bypass will consist of:

Beijing Friendship Hospital, Beijing Tiantan Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, The Third Xiangya Hospital of Central South University, The First Affiliated Hospital of Soochow University, The Third People's Hospital of Chengdu, Taipei Medical University Hospital

Type2 Diabetes, Complication of Bariatric Procedure

10/26

12/26

NCT05493033: Intracorporeal Versus Extracorporeal Anastomotic After Laparoscopic Right Colectomy

Not yet recruiting

N/A

1158

Intracorporeal anastomotic after LRC, Extracorporeal anastomotic after LRC

Beijing Friendship Hospital

Colon Cancer

01/27

01/30

NCT03520699: Beijing Friendship Hospital Metabolic Surgery Database

Recruiting

N/A

3000

RoW

Beijing Friendship Hospital

Metabolic Surgery

12/27

12/28

NCT05061589: Incidence and Risk Factors of Parastomal Hernia in Patients With Permanent Colostomy in China

Not yet recruiting

N/A

712

RoW

permanent colostomy

Beijing Friendship Hospital

Hernia, Stoma Colostomy

05/22

06/22

Xu, Wei

NCT06708156: The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

Recruiting

606

RoW

Atropine sulfate eye drops 0.01%, Atropine sulfate eye drops 0.02%, Placebo eye drops

Oupushifang Pharmaceutical Technology Co., Ltd., Seefunge Pharmaceutical Technology Co., Ltd., AUTEK China Inc.

Myopia, Myopia Progression

12/26

12/27

NCT06953739: A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.

Not yet recruiting

P-GEMD, P-Gemox

The First Affiliated Hospital with Nanjing Medical University

NK-T-Cell Lymphoma, Extranodal

12/27

12/30

NCT05931263: A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Recruiting

104

RoW

C-BEAM Regimen, BEAM Regimen

The First Affiliated Hospital with Nanjing Medical University

Newly Diagnosed Peripheral T-cell Lymphoma

02/26

02/28

ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

2/3

226

RoW

ICP-248, Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Hematologic Malignancies

11/30

07/31

NCT04423926: Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Recruiting

RoW

Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone

The First Affiliated Hospital with Nanjing Medical University

PTCL, NOS, AITL, ALK- ALCL, Phase III-IV ALK+ ALCL, EATL

12/22

12/24

NCT04438005: A Study of ICP-022 in Patients With R/R DLBCL

Completed

RoW

ICP-022

Beijing InnoCare Pharma Tech Co., Ltd.

Diffuse Large B Cell Lymphoma

11/21

12/21

NCT05241132: Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Recruiting

RoW

Tislelizumab plus chemotherapy, Cisplatin, Paclitaxel

Wei Xu

Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab, Gene Mutation-Related Cancer, Immune Evasion, Tumor, Chemotherapy Effect

06/23

10/24

NCT04181489: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Recruiting

RoW

Sintilimab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone

The First Affiliated Hospital with Nanjing Medical University

EBV-Positive DLBCL, Nos

12/23

NCT05186558: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Not yet recruiting

RoW

penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

The First Affiliated Hospital with Nanjing Medical University

Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type

01/24

02/26

NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting

RoW

Rocbrutinib, NWP-775, LP-168

Guangzhou Lupeng Pharmaceutical Company LTD.

Mantle Cell Lymphoma (MCL)

12/24

12/25

NCT06891157: Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

Recruiting

148

RoW

Chidamide plus R-CHOP

The First Affiliated Hospital with Nanjing Medical University

Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)

08/27

NCT06594432: Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement

Not yet recruiting

RoW

R-CHOP+Z+MTX, R-CHOP+MTX

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B Cell Lymphoma (DLBCL)

12/26

06/27

NCT04432714: Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Recruiting

RoW

Lenalidomide, Rituximab, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone

The First Affiliated Hospital with Nanjing Medical University

DLBCL, Untreated, MYC Gene Rearrangement

12/24

12/26

NCT06925555: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

Not yet recruiting

RoW

BV+R-CHP

The First Affiliated Hospital with Nanjing Medical University

EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin

12/28

NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated

1/2

RoW

TQ-B3525 tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

11/23

NCT05323201: Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Recruiting

1/2

RoW

fhB7H3.CAR-Ts, B7H3 targeting chimeric antigen receptor T cells, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan

The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, IIT MediTech Co. Ltd

Hepatocellular Carcinoma

02/24

02/27

TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated

RoW

ATG-019, KPT-9274, ATG-019 + Niacin ER

Antengene Therapeutics Limited

Solid Tumor, Non-Hodgkin's Lymphoma

10/23

TT01488CN02, NCT05683717: A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting

RoW

TT-01488 Tablets

TransThera Sciences (Nanjing), Inc.

B-Cell Malignancies

10/26

10/28

NCT05173467: Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor

Not yet recruiting

N/A

RoW

Robot-assisted Invasion-controlled Surgery, Traditional-open Surgery

Wei Xu

Minimally Invasive Surgery, Spinal Metastases

12/22

12/23

NCT04432402: Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Recruiting

N/A

124

RoW

Lenalidomide, Rituximab, Gemcitabine, oxaliplatin

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B Cell Lymphoma

12/22

12/24

Cryo-InitialAF, NCT04942834: Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

Recruiting

N/A

286

RoW

Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone, cryoballoon ablation

Ruijin Hospital

Atrial Fibrillation, Persistent, Arrhythmias, Cardiac

07/25

01/26

NCT05777369: R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Not yet recruiting

N/A

Rituximab, Mitoxantrone hydrochloride liposome, Cyclophosphamide, Vincristine/Vindesine, Prednisone

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B-cell Lymphoma

08/23

08/24

NCT06211881: Chi-GVM Regimen for the Treatment of R/R PTCL

Recruiting

N/A

RoW

Chi-GVM, Chidamide Combined With Gemcitabine, Vinorelbine, and Mitoxantrone Hydrochloride Liposome

The First Affiliated Hospital with Nanjing Medical University

Relapsed/Refractory Peripheral T-cell Lymphoma

09/25

CSPC-DED-DLBCL-K09, NCT05784987: R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Not yet recruiting

N/A

Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide, Etoposide, X: Orelabrutinib, X: Chidamide, X: Penpulimab, X: Lenalidomide

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B-cell Lymphoma

01/24

01/25

NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting

N/A

1400

Europe, US, RoW

Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation

Medtronic Vascular

Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus

11/26

11/29

EVL, NCT06250803: Early Pancreatic Stent Placement for Preventing PEP

Recruiting

N/A

768

RoW

early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP)

The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Bengbu Medical University, Anqing Municipal Hospital, First Affiliated Hospital of Wannan Medical College, Tongcheng People's Hospital of Anhui province, Fuyang people's hospital

Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis

03/26

COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Recruiting

N/A

380

Canada, US

Arm 1: treatment with Shockwave Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry

Shockwave Medical, Inc., Shockwave Medical, Inc.

Refractory Angina

07/27

01/32

NCT05426824: The Whole-course Management of Pegaspargase in ENKTL

Not yet recruiting

N/A

RoW

Pegaspargase（P-GOD）, Pegaspargase（PEMD）

The First Affiliated Hospital with Nanjing Medical University

Extranodal NK/T Cell Lymphoma

07/24

07/25

NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Active, not recruiting

N/A

1000

RoW

No Intervention

Takeda

Lymphoma

06/26

NCT05896813: CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Recruiting

N/A

RoW

CMOP+Chidamide

The First Affiliated Hospital with Nanjing Medical University

Newly Diagnosed Peripheral T-cell Lymphoma

01/25

EMPOWER CAD, NCT05755711: Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

Active, not recruiting

N/A

399

Europe, US

Shockwave Medical Coronary IVL System

Shockwave Medical, Inc.

Coronary Artery Disease

12/24

04/28

PWH, NCT06940375: Prevelence of Liver Disease-Related Outcomes in People With HIV

Not yet recruiting

N/A

320

RoW

Abdominal ultrasound , Fibroscan and body composition analysis examination, TE, BIA

Shanghai Public Health Clinical Center

MAFLD, Liver Fibrosis, MASH, HIV, Metabolic Syndrome X, Hepatic Steatosis

08/25

NCT05343377: A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

Not yet recruiting

N/A

RoW

circulate free methylated EBV DNA

The First Affiliated Hospital with Nanjing Medical University, Zhenjiang First People's Hospital, Changzhou First People's Hospital, Changzhou Second People's Hospital, Wuxi People's Hospital, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Nantong University, Huaian first people's hospital, Yancheng First People's Hospital

Extranodal Natural Killer/T-cell Lymphoma

06/25

06/28

NCT06120426: En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.

Recruiting

N/A

182

RoW

total en bloc spondylectomy

Shanghai Changzheng Hospital, Peking University Third Hospital, Peking University People's Hospital, Henan Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Zhejiang University, Tianjin Hospital, The First Affiliated Hospital of Nanchang University, The Third Affiliated Hospital of Southern Medical University

Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor, Surgery

07/25

07/27

DRAIN-HF, NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Recruiting

N/A

295

Aortix System, Aortix Pump

Procyrion

Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive

01/26

07/26

NCT05967949: A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting

N/A

200

RoW

chidamide

The First Affiliated Hospital with Nanjing Medical University

PTCL

04/26

04/28

NCT05645302: Intensive Monitoring Scheme of Lidocaine Cataplasms

Recruiting

N/A

200

RoW

Lidocaine Cataplasms

Qianfoshan Hospital

Adverse Reaction to Drug

10/22

12/22

li, linfeng

NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting

400

RoW

HB0017 Q4W, HB0017 Q8W, placebo

Huabo Biopharm Co., Ltd.

Psoriasis

08/24

12/25

NCT06587685: A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis

Recruiting

472

RoW

PG-011Gel, PG-011Gel 3%, Vehicle, placebo

Prime Gene Therapeutics Co., Ltd.

Atopic Dermatitis

12/24

01/26

NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting

430

RoW

Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid

Eli Lilly and Company

Atopic Dermatitis

12/25

11/26

NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Not yet recruiting

500

RoW

TQH2722 injection, Placebo of TQH2722 injection

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Atopic Dermatitis

10/25

06/26

TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting

1300

Europe, Canada, Japan, US, RoW

TAK-279

Takeda

Plaque Psoriasis

05/26

NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis

Recruiting

552

RoW

ICP-332 Tablets, ICP-332 Placebo Tablets

Beijing InnoCare Pharma Tech Co., Ltd.

Atopic Dermatitis

11/26

12/26

NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting

693

Europe, Canada, Japan, US, RoW

TAK-279, Placebo, Apremilast

Takeda

Plaque Psoriasis

08/25

04/26

MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Active, not recruiting

2/3

645

RoW

SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo

Reistone Biopharma Company Limited

Atopic Dermatitis

09/23

07/24

NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Recruiting

RoW

ICP-332, ICP-332 Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Moderate to Severe Atopic Dermatitis

07/23

12/23

NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Recruiting

200

RoW

LP-003, Placebo, Omalizumab

Longbio Pharma

Chronic Spontaneous Urticaria

01/25

NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

Completed

129

RoW

ICP-488 Tablets, ICP-488 Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Moderate to Severe Plaque Psoriasis

08/24

09/24

NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Recruiting

120

RoW

HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets

Hansoh BioMedical R&D Company

Psoriasis

07/24

08/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhang, Zhongtao

RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer

Terminated

RoW

Oxaliplatin plus S-1, SOX, S-1 only, S-1

Peking University Cancer Hospital & Institute

Gastric Cancer

09/21

Active, not recruiting

120

RoW

Merck Sharp & Dohme LLC

Gastric Cancer, Gastroesophageal Junction Cancer

02/24

04/25

NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting

480

RoW

Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Hepatocellular Carcinoma

08/24

12/26

NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting

878

RoW

JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Shanghai Junshi Bioscience Co., Ltd.

Gastric or Esophagogastric Junction Adenocarcinoma

06/26

07/28

TQB3454-III-01, NCT05987358: A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Not yet recruiting

165

RoW

TQB3454 tablets, TQB3454 tablets matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Biliary Carcinoma

12/26

NCT06312982: A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study

Recruiting

2/3

375

RoW

Tislelizumab

Locally Advanced Rectal Carcinoma

12/26

NCT04258657: Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer

Not yet recruiting

RoW

paclitaxel-albumin and S-1

Beijing Friendship Hospital

Gastric Cancer

12/22

NCT04258644: Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Not yet recruiting

RoW

Camrelizumab+Apatinib+Paclitaxel-albumin+S-1

Beijing Friendship Hospital

Gastric Cancer

02/23

Recruiting

244

RoW

concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX

Rectal Cancer, Pathological Complete Response, Disease Free Survival

04/23

06/25

POLAR-STAR, NCT05245474: Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

Recruiting

186

RoW

Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)

Locally Advanced Rectal Cancer

03/24

09/29

NCT06475846: A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

Not yet recruiting

232

RoW

HRS5580, Ondansetron, blank preparation

Fujian Shengdi Pharmaceutical Co., Ltd.

Preventing of Postoperative Nausea and Vomiting in Adults

10/24

11/24

NCT06056804: Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Active, not recruiting

RoW

capecitabine, tislelizumab, thymalfasin, long-term radiotherapy

Beijing Friendship Hospital, Peking Union Medical College Hospital

Locally Advanced Rectal Cancer

12/24

07/27

THYMI, NCT06829355: "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

Recruiting

RoW

Thymalfasin (Thymosin alpha 1, Ta1), Regorafenib (BAY 73-4506), Tislelizumab (BGB-A317)

Beijing Friendship Hospital, Peking Union Medical College Hospital, Peking University People's Hospital

MCRC

12/25

12/27

NCT04461847: ESM Versus OM ï¼šA Randomized Controlled Trial

Recruiting

N/A

287

RoW

subcutaneous mastectomy, endoscopic subcutaneous mastectomy

Beijing Friendship Hospital

Endoscopic Subcutaneous Mastectomy

12/22

POSTER, NCT04012645: Perfusion Outcomes With Near Infrared-Indocyanine Green Imaging System in Laparoscopic Total Mesorectal Excision for Mid- or Low-rectal CanceR

Recruiting

N/A

547

RoW

application of near infrared-indocyanine green imaging system, Non-application of near infrared-indocyanine green imaging system

Rectal Neoplasms

12/23

NACSOC, NCT02972541: Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer

Recruiting

N/A

248

RoW

Stenting with neoadjuvant chemotherapy, Stenting with immediate Surgery

Beijing Chao Yang Hospital

Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction

12/23

NCT06204497: The Safety and Efficiency of Stent-based Diverting Technique Versus Ileostomy in Rectal Cancer Patients

Recruiting

N/A

570

RoW

Stent-based Diverting Technique

Sir Run Run Shaw Hospital

Rectal Neoplasms

12/24

06/25

NCT04366999: Effectiveness of Bariatric Surgery for NAFLD/NASH

Recruiting

N/A

320

RoW

SG, RYGB, OAGB

Bariatric Surgery Candidate, NAFLD, NASH With Fibrosis

12/24

12/26

ORDER, NCT05015283: Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission

Recruiting

N/A

248

RoW

The laparoscopic One-anastomosis gastric bypass will consist of:, The laparoscopic Roux-en-Y gastric bypass will consist of:

Type2 Diabetes, Complication of Bariatric Procedure

10/26

12/26

NCT05493033: Intracorporeal Versus Extracorporeal Anastomotic After Laparoscopic Right Colectomy

Not yet recruiting

N/A

1158

Intracorporeal anastomotic after LRC, Extracorporeal anastomotic after LRC

Beijing Friendship Hospital

Colon Cancer

01/27

01/30

NCT03520699: Beijing Friendship Hospital Metabolic Surgery Database

Recruiting

N/A

3000

RoW

Beijing Friendship Hospital

Metabolic Surgery

12/27

12/28

NCT05061589: Incidence and Risk Factors of Parastomal Hernia in Patients With Permanent Colostomy in China

Not yet recruiting

N/A

712

RoW

permanent colostomy

Beijing Friendship Hospital

Hernia, Stoma Colostomy

05/22

06/22

Xu, Wei

NCT06708156: The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

Recruiting

606

RoW

Atropine sulfate eye drops 0.01%, Atropine sulfate eye drops 0.02%, Placebo eye drops

Oupushifang Pharmaceutical Technology Co., Ltd., Seefunge Pharmaceutical Technology Co., Ltd., AUTEK China Inc.

Myopia, Myopia Progression

12/26

12/27

NCT06953739: A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.

Not yet recruiting

P-GEMD, P-Gemox

The First Affiliated Hospital with Nanjing Medical University

NK-T-Cell Lymphoma, Extranodal

12/27

12/30

NCT05931263: A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Recruiting

104

RoW

C-BEAM Regimen, BEAM Regimen

The First Affiliated Hospital with Nanjing Medical University

Newly Diagnosed Peripheral T-cell Lymphoma

02/26

02/28

ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

2/3

226

RoW

ICP-248, Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Hematologic Malignancies

11/30

07/31

NCT04423926: Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Recruiting

RoW

Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone

The First Affiliated Hospital with Nanjing Medical University

PTCL, NOS, AITL, ALK- ALCL, Phase III-IV ALK+ ALCL, EATL

12/22

12/24

NCT04438005: A Study of ICP-022 in Patients With R/R DLBCL

Completed

RoW

ICP-022

Beijing InnoCare Pharma Tech Co., Ltd.

Diffuse Large B Cell Lymphoma

11/21

12/21

NCT05241132: Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Recruiting

RoW

Tislelizumab plus chemotherapy, Cisplatin, Paclitaxel

Wei Xu

Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab, Gene Mutation-Related Cancer, Immune Evasion, Tumor, Chemotherapy Effect

06/23

10/24

NCT04181489: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Recruiting

RoW

Sintilimab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone

The First Affiliated Hospital with Nanjing Medical University

EBV-Positive DLBCL, Nos

12/23

NCT05186558: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Not yet recruiting

RoW

penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

The First Affiliated Hospital with Nanjing Medical University

Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type

01/24

02/26

NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting

RoW

Rocbrutinib, NWP-775, LP-168

Guangzhou Lupeng Pharmaceutical Company LTD.

Mantle Cell Lymphoma (MCL)

12/24

12/25

NCT06891157: Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

Recruiting

148

RoW

Chidamide plus R-CHOP

The First Affiliated Hospital with Nanjing Medical University

Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)

08/27

NCT06594432: Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement

Not yet recruiting

RoW

R-CHOP+Z+MTX, R-CHOP+MTX

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B Cell Lymphoma (DLBCL)

12/26

06/27

NCT04432714: Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Recruiting

RoW

Lenalidomide, Rituximab, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone

The First Affiliated Hospital with Nanjing Medical University

DLBCL, Untreated, MYC Gene Rearrangement

12/24

12/26

NCT06925555: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

Not yet recruiting

RoW

BV+R-CHP

The First Affiliated Hospital with Nanjing Medical University

EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin

12/28

NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated

1/2

RoW

TQ-B3525 tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

11/23

NCT05323201: Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Recruiting

1/2

RoW

fhB7H3.CAR-Ts, B7H3 targeting chimeric antigen receptor T cells, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan

The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, IIT MediTech Co. Ltd

Hepatocellular Carcinoma

02/24

02/27

TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated

RoW

ATG-019, KPT-9274, ATG-019 + Niacin ER

Antengene Therapeutics Limited

Solid Tumor, Non-Hodgkin's Lymphoma

10/23

TT01488CN02, NCT05683717: A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting

RoW

TT-01488 Tablets

TransThera Sciences (Nanjing), Inc.

B-Cell Malignancies

10/26

10/28

NCT05173467: Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor

Not yet recruiting

N/A

RoW

Robot-assisted Invasion-controlled Surgery, Traditional-open Surgery

Wei Xu

Minimally Invasive Surgery, Spinal Metastases

12/22

12/23

NCT04432402: Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Recruiting

N/A

124

RoW

Lenalidomide, Rituximab, Gemcitabine, oxaliplatin

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B Cell Lymphoma

12/22

12/24

Cryo-InitialAF, NCT04942834: Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

Recruiting

N/A

286

RoW

Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone, cryoballoon ablation

Ruijin Hospital

Atrial Fibrillation, Persistent, Arrhythmias, Cardiac

07/25

01/26

NCT05777369: R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Not yet recruiting

N/A

Rituximab, Mitoxantrone hydrochloride liposome, Cyclophosphamide, Vincristine/Vindesine, Prednisone

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B-cell Lymphoma

08/23

08/24

NCT06211881: Chi-GVM Regimen for the Treatment of R/R PTCL

Recruiting

N/A

RoW

Chi-GVM, Chidamide Combined With Gemcitabine, Vinorelbine, and Mitoxantrone Hydrochloride Liposome

The First Affiliated Hospital with Nanjing Medical University

Relapsed/Refractory Peripheral T-cell Lymphoma

09/25

CSPC-DED-DLBCL-K09, NCT05784987: R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Not yet recruiting

N/A

Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide, Etoposide, X: Orelabrutinib, X: Chidamide, X: Penpulimab, X: Lenalidomide

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B-cell Lymphoma

01/24

01/25

NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting

N/A

1400

Europe, US, RoW

Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation

Medtronic Vascular

Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus

11/26

11/29

EVL, NCT06250803: Early Pancreatic Stent Placement for Preventing PEP

Recruiting

N/A

768

RoW

early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP)

Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis

03/26

COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Recruiting

N/A

380

Canada, US

Arm 1: treatment with Shockwave Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry

Shockwave Medical, Inc., Shockwave Medical, Inc.

Refractory Angina

07/27

01/32

NCT05426824: The Whole-course Management of Pegaspargase in ENKTL

Not yet recruiting

N/A

RoW

Pegaspargase（P-GOD）, Pegaspargase（PEMD）

The First Affiliated Hospital with Nanjing Medical University

Extranodal NK/T Cell Lymphoma

07/24

07/25

NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Active, not recruiting

N/A

1000

RoW

No Intervention

Takeda

Lymphoma

06/26

NCT05896813: CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Recruiting

N/A

RoW

CMOP+Chidamide

The First Affiliated Hospital with Nanjing Medical University

Newly Diagnosed Peripheral T-cell Lymphoma

01/25

EMPOWER CAD, NCT05755711: Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

Active, not recruiting

N/A

399

Europe, US

Shockwave Medical Coronary IVL System

Shockwave Medical, Inc.

Coronary Artery Disease

12/24

04/28

PWH, NCT06940375: Prevelence of Liver Disease-Related Outcomes in People With HIV

Not yet recruiting

N/A

320

RoW

Abdominal ultrasound , Fibroscan and body composition analysis examination, TE, BIA

Shanghai Public Health Clinical Center

MAFLD, Liver Fibrosis, MASH, HIV, Metabolic Syndrome X, Hepatic Steatosis

08/25

NCT05343377: A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

Not yet recruiting

N/A

RoW

circulate free methylated EBV DNA

Extranodal Natural Killer/T-cell Lymphoma

06/25

06/28

NCT06120426: En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.

Recruiting

N/A

182

RoW

total en bloc spondylectomy

Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor, Surgery

07/25

07/27

DRAIN-HF, NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Recruiting

N/A

295

Aortix System, Aortix Pump

Procyrion

Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive

01/26

07/26

NCT05967949: A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting

N/A

200

RoW

chidamide

The First Affiliated Hospital with Nanjing Medical University

PTCL

04/26

04/28

NCT05645302: Intensive Monitoring Scheme of Lidocaine Cataplasms

Recruiting

N/A

200

RoW

Lidocaine Cataplasms

Qianfoshan Hospital

Adverse Reaction to Drug

10/22

12/22

li, linfeng

NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting

400

RoW

HB0017 Q4W, HB0017 Q8W, placebo

Huabo Biopharm Co., Ltd.

Psoriasis

08/24

12/25

NCT06587685: A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis

Recruiting

472

RoW

PG-011Gel, PG-011Gel 3%, Vehicle, placebo

Prime Gene Therapeutics Co., Ltd.

Atopic Dermatitis

12/24

01/26

NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting

430

RoW

Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid

Eli Lilly and Company

Atopic Dermatitis

12/25

11/26

NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Not yet recruiting

500

RoW

TQH2722 injection, Placebo of TQH2722 injection

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Atopic Dermatitis

10/25

06/26

TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting

1300

Europe, Canada, Japan, US, RoW

TAK-279

Takeda

Plaque Psoriasis

05/26

NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis

Recruiting

552

RoW

ICP-332 Tablets, ICP-332 Placebo Tablets

Beijing InnoCare Pharma Tech Co., Ltd.

Atopic Dermatitis

11/26

12/26

NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting

693

Europe, Canada, Japan, US, RoW

TAK-279, Placebo, Apremilast

Takeda

Plaque Psoriasis

08/25

04/26

MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Active, not recruiting

2/3

645

RoW

SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo

Reistone Biopharma Company Limited

Atopic Dermatitis

09/23

07/24

NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Recruiting

RoW

ICP-332, ICP-332 Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Moderate to Severe Atopic Dermatitis

07/23

12/23

NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Recruiting

200

RoW

LP-003, Placebo, Omalizumab

Longbio Pharma

Chronic Spontaneous Urticaria

01/25

NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

Completed

129

RoW

ICP-488 Tablets, ICP-488 Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Moderate to Severe Plaque Psoriasis

08/24

09/24

NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Recruiting

120

RoW

HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets

Hansoh BioMedical R&D Company

Psoriasis

07/24

08/24

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites